Intel stock spikes after report of possible US government stake
Investing.com - Leerink Partners has raised its price target on Roivant Sciences (NASDAQ:ROIV) to $18.00 from $17.00 while maintaining an Outperform rating on the stock. Currently trading at $11.17, the stock sits well below analysts’ average target, with estimates ranging from $12 to $22. According to InvestingPro data, management has been actively buying back shares, demonstrating confidence in the company’s prospects.
The price target increase follows Roivant’s fiscal first quarter 2026 results and reflects adjusted share count assumptions based on management’s commentary regarding share repurchase activity.
Leerink Partners remains bullish on the upcoming brepocitinib Phase 3 topline readout in dermatomyositis (DM), which is on track for the second half of 2025, with the last patient last visit completed in July.
The broader brepocitinib program continues to progress with rapid enrollment in the Phase 3 non-infectious uveitis study and the Phase 2 cutaneous sarcoidosis proof-of-concept trial, with readouts expected in the first half of 2027 and second half of 2026, respectively.
Roivant Sciences ended the quarter with $4.5 billion in consolidated cash, cash equivalents, restricted cash, and marketable securities. InvestingPro analysis shows the company holds more cash than debt on its balance sheet, with liquid assets significantly exceeding short-term obligations. Get deeper insights into Roivant’s financial health and access comprehensive analysis through InvestingPro’s detailed research reports.
In other recent news, Roivant Sciences has announced a new common share repurchase program worth up to $500 million. This follows the completion of their previous $1.5 billion repurchase initiative. Goldman Sachs has resumed coverage on Roivant Sciences with a Buy rating and set a price target of $19.00, based on a discounted cash flow model. The investment bank considers the risk associated with Roivant’s business model, which heavily relies on clinical assets. Additionally, Cantor Fitzgerald reiterated its overweight rating on the company, highlighting the potential of brepocitinib in treating dermatomyositis, with Phase 3 trial results expected in the latter half of 2025. Similarly, H.C. Wainwright maintained its buy rating and $18.00 price target, emphasizing the importance of the upcoming Phase 3 VALOR study for brepocitinib. Guggenheim also reiterated a Buy rating with a $15.00 price target, following a webinar on brepocitinib development. These developments indicate continued interest and confidence from analysts in Roivant Sciences’ future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.